| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Nephrology and Hypertension, Georgetown University, Washington , District of Columbia, United States
2 Nephrology and Hypertension, Georgetown University, Washington, District of Columbia, United States
* To whom correspondence should be addressed. E-mail: wilcoxch{at}georgetown.edu.
Asymmetric (NG,NG)-dimethylarginine (ADMA) inhibits nitric oxide synthases (NOS). ADMA is a risk factor for endothelial dysfunction, cardiovascular mortality and progression of chronic kidney disease. Two isoforms of dimethylarginine dimethylaminohydrolase (DDAH) metabolize ADMA. DDAH-1 is the predominant isoform in the proximal tubules of the kidney and in the liver. These organs extract ADMA from the circulation. DDAH-2 is the predominant isoform in the vasculature where it is found in endothelial cells adjacent to the cell membrane and in intracellular vesicles and in vascular smooth muscle cells among the myofibrils and the nuclear envelope. In vivo gene silencing of DDAH-1 in the rat, and DDAH +/- mice both have increased circulating ADMA whereas gene silencing of DDAH-2 reduces vascular NO generation and endothelium derived relaxation factor responses. DDAH-2 also is expressed in the kidney in the macula densa and distal nephron. Angiotensin type 1 receptor activation in kidneys reduces the expression of DDAH-1 but increases the expression of DDAH-2. This rapidly evolving evidence of isoform-specific distribution and regulation of DDAH expression in the kidney and blood vessels provides potential mechanisms for nephron site-specific regulation of NO production. In this review, the recent advances in the regulation and function of DDAH enzymes, their roles in the regulation of NO generation and their possible contribution to endothelial dysfunction in patients with cardiovascular and kidney diseases is discussed.
This article has been cited by other articles:
|
|
 |
|
  J. Li, A. Wilson, X. Gao, R. Kuruba, Y. Liu, S. Poloyac, B. Pitt, W. Xie, and S. Li Coordinated Regulation of Dimethylarginine Dimethylaminohydrolase-1 and Cationic Amino Acid Transporter-1 by Farnesoid X Receptor in Mouse Liver and Kidney and Its Implication in the Control of Blood Levels of Asymmetric Dimethylarginine J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 234 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Schwedhelm, V. Xanthakis, R. Maas, L. M. Sullivan, F. Schulze, U. Riederer, R. A. Benndorf, R. H. Boger, and R. S. Vasan Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography-Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort Clin. Chem., August 1, 2009; 55(8): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Desai Reply Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1350 - 1351. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, S. Strandgaard, J. Iversen, and C. S. Wilcox Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R195 - R200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Wilcox and A. Pearlman Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
